VO 514
Latest Information Update: 09 Nov 2006
Price :
$50 *
At a glance
- Originator Genentech
- Developer Genentech; Nonindustrial source
- Class Antiplatelets
- Mechanism of Action Integrin alphaVbeta3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary artery restenosis; Vascular restenosis
Most Recent Events
- 09 Nov 2006 Discontinued - Preclinical for Coronary artery restenosis in United Kingdom (unspecified route)
- 09 Nov 2006 Discontinued - Preclinical for Coronary artery restenosis in USA (unspecified route)
- 09 Nov 2006 Discontinued - Preclinical for Vascular restenosis in United Kingdom (unspecified route)